Ultragenyx Pharmaceu (RARE) is trading -19% lower at $49.58 today.

Ultragenyx Pharmaceu has been trading between a 52-week high of $104.38 and a 52-week low of $45.2. The stock has a market cap of $3.47 Billion.

Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.

Ultragenyx to acquire GeneTx after promising data on Angelman syndrome treatment
Seeking Alpha 07-18-22

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Jumps 0.28%: Is This A Sign Of Things To Come?
Stocks Register 07-16-22

Ultragenyx Sells One-Third Of Future North American Crysvita Royalties For $500M
Benzinga 07-14-22

Ultragenyx sells part of North American royalties on Crysvita to OMERS for $500M
Seeking Alpha 07-14-22

Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® (burosumab) for $500 Million to OMERS Capital Markets
GlobeNewswire 07-14-22